Sangamo Therapeutics, Inc. (LON:0R1D)
0.5045
+0.0045 (0.90%)
Dec 9, 2025, 7:10 PM BST
Sangamo Therapeutics Revenue
Sangamo Therapeutics had revenue of $581.00K USD in the quarter ending September 30, 2025, a decrease of -98.82%. This brings the company's revenue in the last twelve months to $32.88M, down -37.13% year-over-year. In the year 2024, Sangamo Therapeutics had annual revenue of $57.80M, down -67.20%.
Revenue (ttm)
$32.88M
Revenue Growth
-37.13%
P/S Ratio
5.20
Revenue / Employee
$179.64K
Employees
183
Market Cap
127.20M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
| Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
| Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
| Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
| Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
| Dec 31, 2019 | 102.43M | 17.98M | 21.29% |
| Dec 31, 2018 | 84.45M | 47.89M | 130.95% |
| Dec 31, 2017 | 36.57M | 17.18M | 88.60% |
| Dec 31, 2016 | 19.39M | -20.15M | -50.96% |
| Dec 31, 2015 | 39.54M | -6.33M | -13.80% |
| Dec 31, 2014 | 45.87M | 21.74M | 90.07% |
| Dec 31, 2013 | 24.13M | 2.48M | 11.44% |
| Dec 31, 2012 | 21.66M | 11.34M | 109.86% |
| Dec 31, 2011 | 10.32M | -10.49M | -50.40% |
| Dec 31, 2010 | 20.81M | -1.38M | -6.23% |
| Dec 31, 2009 | 22.19M | 6.00M | 37.08% |
| Dec 31, 2008 | 16.19M | 7.09M | 77.91% |
| Dec 31, 2007 | 9.10M | 1.21M | 15.38% |
| Dec 31, 2006 | 7.89M | 5.40M | 217.43% |
| Dec 31, 2005 | 2.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Sangamo Therapeutics News
- 7 days ago - Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
- 7 days ago - Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - Seeking Alpha
- 7 days ago - Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
- 7 days ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire
- 18 days ago - Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission - GuruFocus
- 18 days ago - Sangamo rises as FDA accepts rolling submission request for gene therapy - Seeking Alpha
- 18 days ago - FDA Accepts Sangamo's Request For Rolling BLA Submission For Fabry Disease Gene Therapy Candidate - Nasdaq
- 18 days ago - Sangamo (SGMO) Advances Gene Therapy for Fabry Disease with FDA Approval Process - GuruFocus